Anoro▼ Ellipta umeclidinium/vilanterol

Product menu

Hear experts' perspectives and listen to real life patient case studies

Hear from the experts

GSK organised and funded a roundtable meeting with respiratory experts to discuss the health-system impact of LAMA/LABA (IMT) initial maintenance therapy in COPD. Attendees were paid in honorarium for their time by GSK. Watch the videos below to learn more.

Why use LAMA/LABAs as first-line maintenance therapy in specific COPD patients?

Prescribing information

Have you done enough to implement guidelines?

Prescribing information

Why you might want to review COPD patients receiving a LAMA?

Prescribing information

Expert perspectives on LAMA/LABA as first-line maintenance therapy and real life case studies

GSK interviewed respiratory experts Dr Daryl Freeman and Laura Rush to discuss the use of LAMA/LABAs as first-line maintenance therapy for appropriate symptomatic COPD patients and real life COPD case studies. The speakers were paid an honorarium for their time by GSK. Watch the videos below to learn more.

LAMA/LABAs as first-line maintenance therapy for appropriate symptomatic COPD patients

Since this video was recorded, another LAMA/LABA has been made available in the UK; there are currently 5 LAMA/LABAs

Prescribing information

Real life case studies of prescribing LAMA/LABAs

Prescribing information

You might also be interested in…

Dosing & the Ellipta device

Head-to-head data vs. LAMA/LABAs

Molecules

Head-to-head data vs. a LAMA

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.

Innoviva Logo

November 2022 | PM-GB-UCV-WCNT-210008 (V3.0)